MPN (Myeloproliferative Neoplasms) Clinical Trial
Official title:
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
The purpose of this study is to evaluate the efficacy and safety of pemigatinib (INCB054828) in subjects with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1 rearrangement.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03123588 -
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
|
Phase 2 | |
| Completed |
NCT01348490 -
Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
|
Phase 2 | |
| Completed |
NCT02252159 -
Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
|
||
| Completed |
NCT01633372 -
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
|
Phase 2 | |
| Completed |
NCT03144687 -
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
|
Phase 2 | |
| Completed |
NCT02718300 -
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
|
Phase 2 | |
| Completed |
NCT02953704 -
Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
|
||
| Completed |
NCT00952289 -
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
|
Phase 3 |